ChroMedX Corp. Awarded New United States Patent on Ultra Filtration Technology
TORONTO, ONTARIO -- (October 14, 2015) - ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded a United States patent on its Ultra Filtration technology.
ChroMedX was awarded US Pat. No. 9,162,186, entitled "Sample Filtration Assembly". This patent is related to manual ultrafiltration cartridges, and while related to two recently announced Canadian patents on the Company’s Automated Ultrafiltration (AUF) system, presents a new business opportunity for ChroMedX.
One potential application of the technology claimed in US 9,162,186 is to extract plasma from blood during the time blood is drawn from a patient. Usually blood is drawn into a vacuum filled tube, and the plasma is extracted in a central laboratory by centrifuging the tube of blood. By providing plasma separation immediately at the time of sampling, this technology provides a means for POCT that cannot be performed accurately on whole blood. A second claimed application is to provide disposable manual plasma ultrafiltration cartridges for measuring unbound drugs and hormones (i.e. biologically active drugs and hormones), to laboratories that cannot afford an AUF workstation.
This patent further demonstrates the novelty and usefulness of the Company’s ultrafiltration technology and provides ChroMedX with new business opportunities in addition to its HemoPalmTM and AUF technologies.
This patent is a part of the Company’s suite of issued and pending patents covering all of its technologies. A complete list of the Company’s intellectual property can be found on the ChroMedX website at www.chromedx.com
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
o. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.